SWM
REGN icon

SHP Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

SHP Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$38.9K Buy
50
+16
+47% +$12.2K ﹤0.01% 553
2025
Q4 		$26.5K Buy
+34
New +$23.1K ﹤0.01% 619

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SHP Wealth Management's REGN Position: Q1 2026 in Review

SHP Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 47% in Q1 2026, buying an estimated $12.2K and bringing the position to 50 shares worth $38.9K. The position accounts for ﹤0.01% of the portfolio, ranked #553.

SHP Wealth Management first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. 1,396 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • SHP Wealth Management held 50 shares of Regeneron Pharmaceuticals worth $38.9K as of Q1 2026.
  • SHP Wealth Management bought 16 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $12.2K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #553 holding.
  • SHP Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 1,396 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.